단장증후군 시장 - 예측(2026-2031년)

The short bowel syndrome market, at a 6.85% CAGR, is projected to increase from USD 1.953 billion in 2025 to USD 2.906 billion in 2031.

The Short Bowel Syndrome (SBS) market is poised for steady growth, driven by a confluence of clinical, commercial, and regulatory factors. The market's expansion is fundamentally linked to an increasing patient population, heightened clinical awareness, and a progressive pipeline of therapeutic interventions. While growth is anticipated across key regions, the market trajectory is influenced by both significant opportunities and inherent challenges that shape the commercial and research landscape.

A primary catalyst for market growth is the rising global prevalence of gastrointestinal disorders, which are a leading cause of SBS. Conditions such as Crohn's disease, volvulus, and other severe intestinal pathologies often necessitate extensive surgical resection, resulting in intestinal failure. The increasing incidence of these underlying disorders, partly attributed to evolving lifestyle factors, is directly enlarging the addressable patient pool for SBS therapies. This establishes a sustained clinical demand for effective management strategies, fueling market development.

Complementing this demographic driver is a concerted effort to elevate disease understanding among both healthcare providers and patients. Awareness initiatives, spearheaded by specialized organizations and professional societies, are playing a pivotal role. These programs focus on educating stakeholders about intestinal failure, the significant patient burden associated with SBS, and the importance of structured care transitions. By enhancing the diagnostic and treatment paradigm, these initiatives are instrumental in improving patient identification, care standards, and ultimately, the adoption of available and emerging therapies.

The market is further energized by significant scientific and clinical activity. Government and institutional funding is supporting advanced research projects aimed at developing innovative treatments. These include investigations into novel pharmacological agents as well as groundbreaking approaches like tissue engineering. Concurrently, the competitive landscape is dynamic, with key pharmaceutical and biotechnology companies actively engaged in clinical development. The pipeline features several investigational drugs, including long-acting analogs and other targeted therapies, indicating a move towards more effective and convenient treatment modalities. Product launches and the pursuit of regulatory approvals for new compounds are anticipated to be major growth levers, expanding treatment options and market scope.

However, the market's potential is tempered by several restraining factors. A limited number of approved pharmacotherapies, particularly in developing regions, constrains patient access. Furthermore, the side effect profiles associated with certain medications necessitate careful clinical evaluation to ensure a favorable benefit-risk ratio for patients. These pharmacological challenges, combined with disparities in healthcare infrastructure and reimbursement frameworks across different geographies, present barriers to universal market penetration and limit growth in under-resourced settings.

From a geographical perspective, North America is positioned to maintain a substantial market share. This prominence is underpinned by a well-established prevalence of SBS, advanced healthcare infrastructure, and robust investment in biomedical research. The region benefits from the presence of leading market players who are actively investing in research and clinical trials, fostering an ecosystem conducive to innovation and commercial development. The concentration of clinical expertise and research funding in this region continues to attract significant market activity.

In conclusion, the Short Bowel Syndrome market is on a growth trajectory shaped by increasing clinical need and scientific advancement. The expansion of the patient population due to related gastrointestinal disorders provides a solid foundation for demand. This is amplified by strategic awareness campaigns and a vibrant pipeline of investigational therapies supported by research funding. Market players are navigating a path defined by the opportunity to address a serious unmet medical need with innovative treatments, while simultaneously contending with challenges related to drug accessibility, safety, and global healthcare inequities. The evolution of this market will hinge on the successful translation of clinical research into approved, accessible, and well-tolerated therapies that meaningfully improve patient outcomes.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Short Bowel Syndrome Market Segmentation:

BY DRUG CLASS

• Glucagon-like Peptide-2 (GLP2)
• Growth Hormone
• Glutamine
• Others

BY DISTRIBUTION CHANNEL

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales

BY GEOGRAPHY

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SHORT BOWEL SYNDROME MARKET BY DRUG CLASS

• 5.1. Introduction
• 5.2. Glucagon-like Peptide-2 (GLP2)
• 5.3. Growth Hormone
• 5.4. Glutamine
• 5.5. Others

6. SHORT BOWEL SYNDROME MARKET BY DISTRIBUTION CHANNEL

• 6.1. Introduction
• 6.2. Hospital Pharmacies
• 6.3. Retail Pharmacies
• 6.4. Online Sales

7. SHORT BOWEL SYNDROME MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. USA
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others
• 7.4. Europe
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. United Kingdom
  • 7.4.4. Spain
  • 7.4.5. Others
• 7.5. Middle East and Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. Others
• 7.6. Asia Pacific
  • 7.6.1. China
  • 7.6.2. India
  • 7.6.3. Japan
  • 7.6.4. South Korea
  • 7.6.5. Indonesia
  • 7.6.6. Thailand
  • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Market Share Analysis
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Competitive Dashboard

9. COMPANY PROFILES

• 9.1. Takeda Pharmaceutical Company
• 9.2. OxThera Inc.
• 9.3. VectivBio AG
• 9.4. Merck KGaA
• 9.5. Ardelyx
• 9.6. Zealand Pharma
• 9.7. Nestle Health Science
• 9.8. Hanmi Pharm.Co., Ltd

10. APPENDIX

• 10.1. Currency
• 10.2. Assumptions
• 10.3. Base and Forecast Years Timeline
• 10.4. Key Benefits for the Stakeholders
• 10.5. Research Methodology
• 10.6. Abbreviations